Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant type I herpes simplex virus R130 injection (Vero cells)
- Development stage
- Unknown
- Lead developer
- Shanghai Yunying Medical Technology
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intraperitoneal, Intratumoral
01
Overview
Recombinant type I herpes simplex virus R130 injection (Vero cells) is a third-generation recombinant oncolytic herpes simplex virus type 1 (oHSV-1) developed by Shanghai Yunying Medical Technology. Engineered to selectively replicate in and lyse tumor cells, R130 is armed with multiple immunomodulatory transgenes, including an anti-CD3 single-chain variable fragment (scFv), CD86, and PD-1, alongside the HSV-2 US11 gene to enhance viral replication. This multi-pronged design enables R130 to directly destroy cancer cells while simultaneously recruiting and activating T cells within the tumor microenvironment, reversing T-cell exhaustion and promoting a robust systemic anti-tumor immune response. R130 is currently in Early Phase 1 clinical development in China for the treatment of advanced solid tumors, including bone and soft tissue tumors.
- Other names
- Recombinant Herpes Simplex Virus Type I R130 Injection (Vero cell)Recombinant oncolytic herpes simplex virus type 1 (R130)第三代重组溶瘤病毒R130重组I型单纯疱疹病毒R130注射液（Vero细胞）
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)CD86 (T-lymphocyte activation antigen CD86)CD274 (Programmed cell death protein 1 ligand 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on recombinant type I herpes simplex virus R130 injection (Vero cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant type I herpes simplex virus R130 injection (Vero cells).